DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

Trends in Reimbursement of Biologics Across the Growth Markets: Focus on Argentina, Brazil, and Mexico

Most patients in Argentina, Brazil, and Mexico rely on social security or public healthcare drug coverage programs with limited funds for premium-priced agents; the social security institutions and national health organizations limit the use of costly agents, particularly biologics, to well-defined target populations or the less numerous groups of patients who have undergone several rounds of previous treatment. In an environment where a wealth of therapeutic options is available, only those drugs that show considerable benefit over existing agents or those that are highly likely to have a therapeutic effect through appropriate patient selection receive reimbursement. In recent years, all three markets have established multiple health technology assessments as a necessary step following a new drug’s approval. As a result, while an approval from the regulatory bodies of Argentina (ANMAT), Brazil (ANVISA), and Mexico (COFEPRIS) may be received shortly after a drug’s approval in the major pharmaceutical markets, it may precede inclusion on relevant formularies by several years.

Questions Answered in This Report:

  • Argentina, Brazil, and Mexico represent countries with a mix of health coverage provisions, including social security, public programs, and private systems. What are the drug access programs that cover biological agents across the three countries? What are the payers’ perceptions regarding biologics coverage?

  • With the introduction of premium-priced agents, healthcare costs continue to rise in the major and growth markets. Does drug authorization guarantee market access? What are the current access hurdles? What types of drugs are favored for reimbursement?

  • Prices of biological agents vary widely between Argentina, Brazil, and Mexico. How do these prices compare with the United States? How are drug prices negotiated? What is the treatment burden to individual patients?